6th April 2013 - New research


Movement Disorders [2013] Mar 11 [Epub ahead of print] (Y.Mizuno Y, Kondo, the Japanese Istradefylline Study Group) Complete abstract

Researchers evaluated the efficacy and safety of istradefylline, which is being developed for the treatment of Parkinson's Disease. Istradefylline is an A(2A) adenosine receptor antagonist and so does not act by directly increasing the activity of dopamine. It is administered with L-dopa.

After a 12 week clinical trial using 20mg or 40mg  istradefylline the change in daily OFF time was significantly reduced with 20mg per day and 40 mg per day. The daily OFF time was over 40 minutes less.  However, the most common adverse event was dyskinesia, which occurred more commonly when taking istradefylline than when taking a placebo. For a printable version of this article click here. For more news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports


2006-2013  Viartis
2015-08-23 02:18:53
[email protected]